News

Winn-Dixie adopts Bi-Lo’s price optimization tool

BY Michael Johnsen

CINCINNATI — KSS Retail, a Dunnhumby company, on Thursday announced that Bi-Lo, the Jacksonville, Fla.-based parent company of Bi-Lo and Winn-Dixie grocery stores, has extended its business relationship with KSS Retail.

What began as an assignment with the Bi-Lo banner now has grown to include price modeling and optimization services for the Winn-Dixie banner.

“The KSS price optimization tool has strengthened BI-LO’s value message with consumers by focusing their pricing efforts on the right items and the right locations,” stated Bruce Steadman, group VP local merchandising and owned brands. “The combined company will leverage this success across both banners, further enhancing the customer experience and ensuring that customers are provided with the best possible prices on all the products they regularly purchase with us.”

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

Lundbeck adds Omnicare to limited distribution network for Huntington’s drug

BY Alaric DeArment

ORLANDO, Fla. — The specialty pharmacy operated by Omnicare Specialty Care Group has been added to the limited distribution network for a drug used to treat a hereditary degenerative disorder.

Omnicare said Friday that Lundbeck had added Advanced Care Scripts to its network for Xenaziner (tetrabenazine). The drug is used to treat involuntary movements known as chorea associated with Huntington’s disease. Chroea affects about 90% of people with Huntington’s and is considered a hallmark of the disease, according to studies.

"As the only approved treatment for chorea, Xenazine represents an important advancement for patients with Huntington’s disease," Omnicare SVP David Hileman said. "We are please to be part of this innovative drug’s limited distribution network and the exclusive partner of product in the long-term care channel."

Huntington’s affects about 1-in-10,000 Americans, and about 200,000 people are at risk of developing it, according to the Huntington’s Disease Society of America, which says every child of a parent with the disease has a 50% chance of inheriting the gene that causes it.

ACS will dispense the drug using blister packs, which Hileman said would improve safety and adherence while reducing the risk of dosing errors and allow better coordination of combined therapies. "We offer this simplified solution to help patients with Huntington’s disease manage their prescription regimens," Hileman said.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter. 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
News

FDA highlights rare instance of burns associated with use of external analgesics

BY Michael Johnsen

 SILVER SPRING, Md. — The Food and Drug Administration on Thursday alerted the public that certain external analgesics have been associated with burns. Most of the reported cases involved products containing higher concentrations of menthol and methyl salicylate (greater than 3% menthol or 10% methyl salicylate). Few of the cases involved capsaicin, the FDA reported. 

Over 42 years, as many as 43 reported cases of burns associated with use of external pain relievers for muscle pain or joint pain have been reported, noted FDA chemist Reynold Tan. While that represents a small incidence relative to the number of external analgesics sold, those products should not be causing burns. 

"[However,] existing Tentative Final Monograph does not at this time require labels of OTC topical muscle and joint pain relievers to carry a warning that use of the products could result in serious burns," the FDA stated. The FDA advised consumers using these products to not bandage the area of pain tightly or apply local heat (e.g., heating pads, lamps, hot water). Further, the FDA advised consumers to not use external analgesics on broken or irritated skin. 

For the 52 weeks ended Aug. 12, sales of external analgesic rubs totaled $305.9 million, up 1.7%, across food, drug and mass (minus Walmart) channels, according to SymphonyIRI Group data. 

 

 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?